Ratings Arecor Therapeutics plc

Equities

Market Closed - London S.E. Other stock markets 16:35:14 29/04/2024 BST			5-day change	1st Jan Change
136.5 ^GBX	0.00%		+3.02%	-25.21%

04-23	Arecor chief financial officer to leave in July after five years	AN
04-23	Arecor Therapeutics CFO to Leave in July	MT

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.

	1st Jan change	Capi.	ESG Refinitiv
ARECOR THERAPEUTICS PLC	-25.21%	52.07M	-
IQVIA HOLDINGS INC.	+2.34%	42.75B	B
LONZA GROUP AG	+47.70%	41.61B	A
MODERNA, INC.	+11.96%	41.34B	B-
CELLTRION, INC.	-12.36%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+8.73%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.82%	18.12B	B
MEDPACE HOLDINGS, INC.	+30.86%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.47%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+8.48%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality